Skip to main content
Heliyon logoLink to Heliyon
. 2024 Jan 17;10(2):e24873. doi: 10.1016/j.heliyon.2024.e24873

MAML2 gene rearrangement occurs in all Warthin-like mucoepidermoid carcinoma: A reappraisal in a series of 29 cases

Xi Wang a,c, Lingchao Liu b, Huiying He b,∗∗, Binbin Li a,c,
PMCID: PMC10831721  PMID: 38304779

Abstract

Background

Warthin-like Mucoepidermoid carcinoma (MEC) is a new and rare morphological variant of MEC, with only a few case reports in the literature. The clinicopathological, molecular features and bio-behaviors of Warthin-like MEC has not been studied extensively. We reappraisal all Warthin-like MEC patients diagnosed and treated at our hospital.

Methods

Patient characteristics including clinicopathological features, genetic aberrations, treatment, and prognostic information were assessed and evaluated.

Results

Twenty-nine Warthin-like MEC patients were identified, 19 patients were female (65.5 %), and 10 were male (34.5 %). The patients’ age varied widely from 8 to 68 years (mean 42.3 years). Genetic aberrations of MAML2 rearrangement were detected in all Warthin-like MEC patients, which suggesting this genetic event is the unique feature of Warthin-like MEC. Twenty-five patients (86.2 %) were assessed as having a low-stage disease (I/II), and four (13.8 %) as having high-clinical stage disease (III/IV). More than half of the patients (16/29) underwent only partial sialoadenectomy; 2 patients underwent extended sialoadenectomy, and 11 patients underwent extended sialoadenectomy with cervical lymph node dissection. After a median follow-up time of 73 months (5–128 months), Twenty-eight patients were alive without recurrence at the end of the follow-up period, one patient died 1 year after surgery due to lung metastasis.

Conclusion

Our data suggested that most Warthin-like MEC exhibited mild clinicopathological course and less aggressive bio-behavior, and an aggressive bio-behavior seemed to be very rare. In addition, in the salivary gland, MAML2 rearrangement seems to be a unique molecular feature of salivary Warthin-like MEC.

Keywords: Warthin-like mucoepidermoid carcinoma, Warthin tumor, MAML2 rearrangement, Clinicopathological features

1. Introduction

Mucoepidermoid carcinoma (MEC) is a highly heterogeneous neoplasm arising mainly from salivary glands [1,2]. MEC shows a broad spectrum of morphologies [3,4]. Typical MEC mainly comprises mucous, intermedia, and epidermoid cells, although clear, oncocytic, mucoacinar and spindle cell-predominant variants of MEC also exist [[5], [6], [7]]. An unusual histologic appearance of the oncocytic epithelium with dense lymphoid infiltration has been identified in some MEC cases. The first report describing a multilayered oncocytic epithelium and nests of squamous and mucous cells in MEC was published by Garcia et al. (García et al., 2011) Six cases were initially diagnosed as oncocytic MEC with a large number of Warthin-like lymphoid stroma. Subsequently, Ishibashi et al. formally proposed and named the variant of Warthin-like MEC in 2015 [8]. In practical diagnosis, it is difficult to differentiate Warthin-like MEC from metaplastic Warthin tumor (mWT), especially when the histologic image shows an atypical bi-layered oncocytic epithelium with dense lymphoid infiltration with or without a small focal group of mucous cells in MEC. The diagnostic criteria of Warthin-like MEC are vague. In addition, as a new subtype of MEC, there are few data on Warthin-like MEC. Therefore, investigation of its specific clinical, histological, and genomic features is needed to facilitate accurate diagnosis and treatment.

Recent studies have demonstrated that 33.7–85.5 % of MECs harbor the CREB-regulated transcriptional co-activator 1 (CRTC1)-mastermind-like gene family-2 (MAML2) translocation, which is associated with low-grade (LG) or intermediate-grade (IG) MEC [9,10]. The fusion product is formed by CRTC1 (also known as MECT1, TORC1, and WAMTP1), a CREB transcriptional coactivator gene in chromosome band 19p13, and the transcriptional coactivator MAML2 in the N-terminal Notch-binding domain of chromosome band 11q12. This translocation was discovered by Nordkvist et al. and Tonon et al. [11,12]. Subsequently, CRTC3, which has 32 % homology with CRTC1, was identified by Fehr [13] to form the CRTC3-MAML2 fusion gene in MEC, which results from the translocation t (11 ∼ 15) (q21; q26) [14]. CRTC1, as a member of the CREB family, regulates cellular metabolism and growth by co-activating CREB-mediated transcription. As a member of a transcriptional coactivation family, MAML2 exerts its biological function mainly via the transcriptional activation of Notch target genes [15]. The fusion protein is a nuclear protein with no enzymatic activity. MAML2 rearrangement may provide an auxiliary cue for Warthin-like MEC diagnosis.

In this study, we collected all patients with Warthin-like MEC of head and neck diagnosed and treated at our hospital between 2005 and 2020, and analyzed the clinicopathological and the presence of MAML2 by FISH in Warthin-like MECs in order to increase the understanding of the diagnosis and guide treatment of Warthin-like MEC.

2. Material and methods

This retrospective study was approved by the Institutional Review Board of the Peking University School and Hospital of Stomatology (PKUSSIRB-201948111).

2.1. Case selection

Six hundred and eighteen cases of head-and-neck MEC were identified from the surgical pathology database between January 2005 and July 2020. All hematoxylin and eosin (H&E)-stained slides were reviewed and re-graded by two head-and-neck pathologists (Binbin Li and Huiying He). Inclusion criteria of Warthin-like MEC: i) MEC diagnosed according to the criteria of WHO Classifications of Head and Neck Tumors (2022). (MEC is composed of mucinous, intermediate (clear-cell) and squamoid tumor cells forming cystic and solid patterns). ii) Additionally, all cases histologically consisted of the diversity of cystic lining oncocytic epithelium and dense lymphoid stroma, with epithelial components arranged in a papillary cystic pattern. Each case was re-graded using the AFIP [16], Brandwein [17], Healey [18] and MSK [19] grading systems by two pathologists. Cases with metastatic MEC from other primary lesions and secondary tumors were excluded. Inclusion criteria of metaplastic Warthin tumor (mWT): i) WT diagnosed according to the criteria of WHO Classifications of Head and Neck Tumors (2022). (Warthin Tumor is composed of oncocytic epithelial cells lining ductal, papillary, and cystic structures in a lymphoid stroma); ii) metaplastic changes of mucinous and/or epidermoid. Furthermore the following criteria were used to exclude the malignant transformation of WT: i) the presence of a pre-existing benign WT; ii) the presence of transition zones from benign oncocytic to malignant epithelial; iii) infiltrating growth in the surrounding lymphoid tissue; iv) exclusion of metastases to the lymphoid stroma component of a primary extra salivary tumor [20]. Diagnostic H&E-stained slides and formalin-fixed paraffin-embedded (FFPE) blocks were retrieved from the surgical pathology archives.

Clinical characteristics were obtained from the electronic medical records, including the age at the time of diagnosis, sex, tumor site, symptoms, smoking history and signs, the interval between initial symptoms and histologic verification, surgical treatment (local resection, complete resection with or without neck lymph node dissection), and adjuvant treatment (radiation therapy, chemotherapy, and/or I125 seed implantation). The tumors were staged according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th edition [21]. Recurrence was determined based on clinical examination or imaging studies and confirmed via fine-needle aspiration or biopsy.

Patient status at the last follow-up was classified as follows: no evidence of disease, alive with disease, and died of disease. Clinical follow-up information was available for all chosen cases.

2.2. Histological evaluation

H&E staining was performed according to standard procedures. Briefly, sections of 4 μm thickness were generated from paraffin-embedded tissue and mounted on slides. After deparaffinization and rehydration, the sections were stained with Mayer's hematoxylin solution and 0.125 % eosin. Following staining, the sections were washed, dehydrated, decalcified, and mounted with neutral balsam mountant. After H&E staining, the tumor size, growth pattern (well-defined/peripheral growth in nests and islands), increase in mitosis (4+, 2–3, or 0–1/10 high-power field [HPF]), tumor necrosis status, the incidence of atypical mitosis, nuclear pleomorphism status, the proportion of mucous cells, intracystic component (solid, <50 %, <25 %), and presence of perineural invasion, bone invasion, vascular invasion, muscle invasion, lymph node metastasis, and distant metastasis were evaluated.

2.3. Fluorescent in situ hybridization

All Paraffin-embedded sections were assessed by MAML2 probes for fluorescence in situ hybridization (FISH). The probes were dual-color break-apart probes. One probe was a 680-kb fragment of the 5′ MAML2 gene labeled with ZyGreen, and the other was a 370-kb fragment of the 3′ MAML2 gene labeled with ZyOrange (Z-2014-200, Zytovision, Bremerhaven, Germany). Briefly, 3-μm sections on slides were baked at 60 °C for 2 h, deparaffinized in xylene twice for 10 min (Decon Laboratories Inc., King of Prussia, PA), and dehydrated twice with 100 % alcohol. They were pretreated using the Vysis Paraffin Pretreatment Kit (Abbott Park, IL). The slides were digested for 30 min in protease solution (0.5 mg/mL) at room temperature, followed by denaturation for 5 min in 70 % formamide (Chemicon, Billerica, MA) and dehydration in ethanol. The slides were incubated with the probes overnight in a humidified chamber at 37 °C. The probes were denatured for 5 min before hybridization at room temperature. Post-hybridization washes were carried out using 0.3 % NP40/2 × SSC at 73 °C for 2 min and subsequently, 0.3 % NP40/2 × SSC at room temperature for 1 min. The slides were air-dried in the dark and counterstained with 3 μL of 4,6-diamino-2-phenylindole (DAPI; Vysis). One hundred randomly selected nonoverlapping tumor cells were manually evaluated for the presence of orange and green or yellow fluorescent signals and the percent split signal was recorded. Positive cases were defined as more than 15 % break-apart signals [22].

2.4. Statistical analysis

Statistical analysis was performed using Student t-test and Fisher's exact tests. Survival analysis was performed using the Kaplan-Meier and Life Table method. Statistical programming was conducted in R (v. 4.0.0) and GraphPad Prism (v. 9.0), using the packages ggplot2. P < 0 0.05 (2-tailed) was considered indicative of statistical significance.

3. Results

3.1. Clinical features

The clinicopathological features of 29 Warthin-like MECs are listed in Table 1. Among the patients diagnosed with Warthin-like MEC, 34.5 % (10/29) were males and 65.5 % (19/29) were females, giving a ratio of approximately 1:2. The patients’ age varied widely from 8 to 68 years (mean 42.3 years). The mean tumor size was 1.9 cm (0.4–4.0 cm). The most frequent site was the parotid gland, accounting for 62.1 % of all cases, followed by the sublingual gland, mandible, tongue, and infratemporal fossa. Two patients had a history of smoking (6.9 %); one of 2 years and the other of >30 years. There were three alcohol drinkers (10.3 %). Seven patients were symptomatic, of which the most common symptom was pain (13.8 %, 4/29), whereas swelling, numbness, and restricted mouth opening were presented in one patient each. The mean interval between the initial symptoms and diagnosis was 21 months (1–180 months). Twenty-five patients (86.2 %) were assessed as having a low-stage disease (I/II), and four (13.8 %) as having high-clinical stage disease (III/IV).

Table 1.

Clinicopathological characteristics of patients with Warthin-like MEC.

Warthin-like MEC
Evaluable patients, N 29
Age, years, n (%)
 <50 16 (55.2)
 ≥50 13 (44.8)
 Mean (range) 42.3 (8–68)
Gender, n (%)
 Male 10 (34.5)
 Female 19 (65.5)
 Smoking history, n (%) 2 (6.9)
Location, n (%)
 Parotid gland 18 (62.1)
 Other sites 11 (37.9)
Tumor size (cm)
 Mean (range) 1.9 (0.4–4)
 Well circumscribed 1 (3.4)
 Cellular atypia (mild, moderate and severe) 26,1,2 (90.7,3.4,7.9)
 Necrosis 3 (7.9)
 Invasive growth 20 (69.0)
Nodal status
 Positive 3 (10.3)
 Negative 26 (89.7)
Stage,n (%)
 Ⅰ+Ⅱ 25 (86.2)
 Ⅲ+Ⅳ 4 (13.8)
Histology Grade system (LG, IG, HG, %)
 AFIP 82.8,6.9,10.3
 Brandwein 20.7,13.8,65.5
 Modified Healy 69.0,20.7,10.3
 Katabi 48.3,41.4,10.3
Treatment, n (%)
 Resection only 18 (62.1)
 Extended resection & cervical Lymph node dissection 11 (37.9)
Adjuvant treatment, n (%)
 rRdiation 5 (17.2)
 I125 seed implantation 4 (13.8)
 Follow up 5-128 (73.3)
Prognosis, n (%)
 Live without recurrent 28 (96.6)
 Recurrence, metastasis, and Death of disease 1 (3.4)

Note: N: number.

Seventeen mWT cases were included. The mean age of mWT patients was 62.23 years with a range of 33–80 years. The male: female ratio was approximately 4:1. A history of cigarette smoking was noted in eight patients (50 %). Alcohol intake was also documented (13 patients did not consume alcohol, and 4 patients consumed more than 30 g of alcohol daily). The mean tumor size was 3 cm (range 2–8 cm). All patients were treated with parotidectomy. None of the patients experienced recurrence during follow-up (mean 31 months, range 6–69 months). The patients with Warthin-like MEC were younger and had smaller tumors than did those with mWTs.

3.2. Histologic features

Microscopically, each Warthin-like MEC consisted of multiple cysts of various shapes and sizes under low magnification (Fig. 1A). The cysts were filled with eosinophilic substances and infiltrated by dense lymphocytes (Fig. 1B). Cystic spaces were lined by mono-layered, disorganized bi-layered and multilayered oncocytic cells (Fig. 1C–E). The cells were flattened with vacuolar nuclei. These oncocytes cells are more likely the squamoid cells. A transition zone between the disorganized bi-layered and mono-/multilayered oncocytic epithelia was observed in most Warthin-like MEC patients. The forms of oncocytic epithelium are diverse. In addition, the cords of squamoid cells were usually accompanied by areas of mucous cells. The germinal center was found frequently in the stroma. Extensive hyalinization and mucus extravasation were also observed. Peripheral growth in nests and islands was observed in 20 (69.0 %) patients. Lymphovascular invasion was noted in 3 patients (10.3 %), perineural invasion in 1 patient (3.4 %), and bone invasion, tumor necrosis and moderate or severe cellular atypia were present in 3 patients (10.3 %)(Table S1).

Fig. 1.

Fig. 1

Histopathological features of Warthin like-MEC (A-E) and mWT(F). A: Typical feature of Warthin-like MEC under low magnification (HEX100); B: Dense lymphocytes (HEX200); C–E: mono-layered, disorganized bi-layered and multilayered oncocytic epithelia in Warthin like-MEC (HEX400); F: Typical bi-layered tumor epithelium in mWTs (HEX400); G: MAML2 fusion positive in Warthin-Like MEC ( × 1000); H: MAML2 negative in mWT ( × 1000). Note: HE: hematoxylin and eosin; mWT: metaplastic Warthin Tumor; Warthin-Like MEC: Warthin-Like Mucoepidermoid Carcinoma. FISH: Fluorescence In situ hybridization.

The 29 cases of Warthin-like MEC were graded according to the four grading systems as follows: AFIP, 24 (82.8 %) LG, 2 (6.9 %) IG, 3 (10.3 %) HG; Brandwein, 6 (20.7 %) LG, 4 (13.8 %) IG, 19 (65.5 %) HG; Katabi, 14 (48.3 %) LG, 12 (41.4 %) IG, 3 (10.3 %) HG; and modified Healy grading, 20 (69.0 %) LG, 6 (20.7 %) IG, 3 (10.3 %) HG. Only the grades of 31.0 % (9/29) of the patients achieved consensus among all four grading systems. Twenty LG tumors according to AFIP grading were upgraded to IG or HG tumors according to the Brandwein grading system. Modified Healy and Katabi grading were inconsistent for 27.6 % of the patients (8/29). One case met the criteria for an HG tumor for all four grading systems. The grades of 29 Warthin-like MECs based on the four grading systems are shown in Table 1.

Of the 17 mWTs, squamous metaplasia was encountered in 41.2 % (7/17) and was often associated with ischemic necrosis. Mucinous metaplasia appeared in 58.8 % (10/17) of the patients. The mucous cells were often large, resembling goblet cells, and interspersed within the oncocytic epithelium as single cells or cell clusters. The typical bi-layered tumor epithelium was always found in the mWTs (Fig. 1F). The key features for differential diagnosis of salivary Warthin-like MEC and mWT were listed in Table 2.

Table 2.

Summary of key points in differential diagnosis of salivary Warthin-like MEC, MEC with TALP and mWT.

Tumor genesis Tumor parenchyma
Tumor mesenchymal
Molecular signature
structure Oncocytic Cell Epidermoid cell Mucus cell Lymphocytes Mucus extravasation
Warthin-like MEC MEC excretory ducts glandular architecture with cystic structures The diversity of cystic lining epithelial and the transition zone between the disorganized bi-layered oncocytic epithelium and mono-/multi-layered oncocytic epithelium appeared Epidermoid Mucus- producing cells Dense lymphocytic infiltrate with lymphoid follicle occur CRTC1/3-MAML2 rearrangement
MEC with TALP Solid or cystic structures Lack the diversity of cystic lining oncocytic epithelium
mWT excretory ducts Papillary architecture Typical bi-layered oncocytic cells. Focal Nonkeratinized squamoid cells mucoid metaplasia accompanied with necrosis, haemorrhages and fibrosis. Dense lymphocytic infiltrate with lymphoid follicle absent Non-specific

Note MEC: mucoepidermoid carcinoma, TALP: Tumor-associated lymphoid proliferation (TALP), mWT: Metaplastic Warthin tumor.

3.3. MAML2 rearrangement tested by FISH

The MAML2 rearrangement was positively detected in all 29 Warthin-like MEC cases. Signals indicating translocation were detected in 23.0–95 % (median 61 %) of the fusion-positive cases. 17 mWT cases were included, and all of them lack MAML2 rearrangement. Representative FISH images are shown in Fig. 1G and H.

3.4. Treatment and follow-up information

More than half of the patients (18/29, 62 %) underwent extended resection of the mass, and 11 (38 %) patients underwent extended resection of the mass and cervical lymph node dissection. Five patients underwent postoperative radiotherapy, and four patients underwent I125 seed implantation. However, there is no relationship between excision modality and prognosis in the Warthin-like MEC patients (P = 0.448). Follow-up information was available for all patients, and the mean follow-up time was 73 months (5–128 months). The detailed outcomes of the cohort are listed in Table 1. At the end of follow-up, one patient died. The time between the surgery and the first recurrence was 12 months, and lung metastases were observed at the same time. Twenty-eight patients were alive without recurrence at the end of the follow-up period (5–128 months). The overall survival rate of 29 Warthin-like MEC patients was 97.0 %. Fig. 2 displays the OS curve for Warthin-like MEC patients.

Fig. 2.

Fig. 2

Kaplan-Meier overall survival curve of Warthin-Like Mucoepidermoid Carcinoma patients.

4. Discussion

Owing to its relative scarcity and novelty, few case reports of Warthin-like MEC have been reported in the English-language literature [[23], [24], [25], [26]]; García et al., 2011 [[27], [28], [29]]; from 2015 to now, all occurred in the parotid gland, and most were painless masses with progressive enlargement. Few patients reported pain or a history of numbness, suggesting indolent malignancy. The overall prognosis of the patients was favorable; only one case recurred 4 years after the operation [28].

In this study, we analyzed the clinicopathological and genetical features of the 29 cases of Warthin-like MEC in head and neck, which is the largest single-center retrospective study of this kind reported in English literature to date.

Patients with salivary gland MEC have a wide age range, from 7 to 86 years old, with a similar mean and median age of 47 years [30]. In Andrew et al. study [9], the average age of the MEC with MAML2 rearrangement patients was 49.3 years. The ratio of male: female was almost 1:1 (26:27). The most frequent primary site was the parotid gland. The histological grading of LG, IntG and HG was 34(64 %),18(32 %) and 1 (2 %). And TNM stage I and II accounted for 73 %, III and IV accounted for 26 %. In the present study, the ages of the Warthin-like MEC patients ranged from 8 to 68 years old, with a mean age of 42.3 years and a median of 45 years. They were just slightly younger. In Nishimura et al.'s review of 238 cases of Warthin tumor, the age distribution ranged from 20 to 85 years with a mean age of 63 years [31]. However, in comparison to Warthin tumor, Warthin-like MEC patients were significantly younger. The male-to-female ratio of Warthin-like MEC in the present study was 1:2, showing a predilection towards females, which is consistent with the results of MEC reported by Taniuchi [32]. On the contrary, Warthin tumor was seen predominantly in male patients (Male/Female: 7/1) in previous study [33].

The clinical presentation of most MEC usually is nonspecific. Its characteristic feature is spontaneous pain/tenderness or adhesion to the surrounding tissue [32]. In the present study, the disease duration after first detection of a mass ranged from 2 month to 15 years. A painless mass is the most common presenting sign. Pain, swelling, numbness, and restricted mouth opening, were unusual symptoms in our data. Obvious cervical lymph node involvement is detected clinically about 26 % of patients with salivary gland MEC. In our study, regional lymph nodes metastasis was only observed in 10.3 % (3/29) of patients of salivary Warthin-like MEC, which was significantly lower than MEC with MAML2 rearrangement patients (17 %) [9].

The histological features of Warthin-like MEC are characteristic and identical to disorganized bilayer oncocytic epithelial and abundant lymphoid stroma. At least partially, classic histologic cell types of MEC (mucinous cells, intermediate cells, and epidermoid cells) can be observed. In some Warthin-like MEC, extensive hyalinization and mucus extravasation could be observed. In salivary gland tumor, an mWT should be considered for distinction from Warthin-like MEC. Commonly, smoking was likely to trigger the development of an mWT. And the male was the most suspicious population. Histologically, only 1.8 % WT presented significant squamous or mucinous metaplasia [34]. Acute, chronic infection, injury, FNAB may be the cause of metaplasia in WT. Squamous metaplastic lesion is commonly accompanied by extensive hemorrhage, necrosis, and infarction and it is often related to the previous FNAB procedures. In the Mucinous metaplasia area, cells with clear and polarized nuclei resembling goblet cells interspersed with the layers of the oncocytic epithelium. And the oncocytes changes possibly following the damage to the mitochondrial DNA induced by smoking. The accurate differential diagnosis of mWT is as following: the epithelial structure is the typical glandular epithelium dominated by high columnar cells; multiple foci of classic bi-layered oncocytic epithelium in an mWT; lymphocytes and a germinal center in the stroma. Key points in the differential diagnosis of Warthin-like MEC, mWT and MEC with tumor-associated lymphoid proliferation were shown in Table 2. Caution is needed to avoid misidentifying an mWT with multilayered oncocytic cells as Warthin-like MEC in cases lacking a solid nest of epidermoid cells. By contrast, a glandular epithelial structure points to a diagnosis of mWT.

In the present study, most Warthin-like MEC were low-grade and have a good prognosis, but rarely, the high-grade Warthin-like MEC still show the ability for distant metastasis. Except the aggressive histological phenotypes,the intermediate/high-grade Warthin-like MEC cases fulfill both morphological and molecular criteria for the diagnosis of Warthin-like MEC. Salivary MEC is characterized by a high degree of tumoral heterogeneity. And in clinical, the most widely used grading systems are the AFIP and Brandwein grading system, Healey grade, and the MSK grading system. However, histology grading is subjective and varies significantly among grading systems. Our data suggests that the heterogeneity of Warthin-like MEC is a factor that makes some limitations in accurate prognosis prediction and individualized precision therapy. Evaluation of detailed histological characteristics and molecular spectrums of the masses of Warthin-like MEC has pivotal importance to create comprehensive, clinically useful, and precise diagnoses. Owing to the smaller number of high-grade Warthin-like MEC cases in the present study, the clinicopathological characteristic and bio-behaviors of high-grade Warthin-like MEC need to be investigated further.

In the present study, all Warthin-like MEC patients had MAML2 rearrangement, a finding consistent with the data on existing literatures. The results indicated that MAML2 rearrangement might be a critical biological process contributing to the development of Warthin-like MEC.

In the study by Fehr et al., the 5-year overall survival rates of patients with MEC were 79.7 % [35]. In the present study, the overall 5-year survival rate of patients with salivary Warthin-like MEC was 97.0 %, which is higher than those of previous studies of patients with salivary MEC. Radiotherapy is used as first-line therapy for advanced or relapsed MEC patients who are not candidate for surgery. In the present study, although most patients are low-grade, 9 out of 29 patients still underwent postoperative radiotherapy. The exact importance of postoperative radiotherapy in salivary Warthin-like MEC is still inconclusive. A prospective study of salivary Warthin-like MEC who are undergoing a uniform treatment regimen and who have follow-up information will reflect patient outcomes more accurately.

As a group of rare and heterogeneous tumors, Warthin-like Mucoepidermoid carcinoma represents a challenge for precise diagnosis. The main strength of this study is the relatively larger sample size compared to studies currently reported. Another strength is the long follow-up period which increases the clinical relevance of outcomes.

In conclusion, this study indicated that Warthin-like MEC, as a rarely and uncommon subtype of MEC, most exhibited mild clinicopathological course and less aggressive bio-behavior, and an aggressive bio-behavior seems to be very rare. In addition, in the salivary gland, MAML2 rearrangement seems to be a unique molecular feature of salivary Warthin-like MEC. Surgery can yield a satisfactory prognosis for most Warthin-like MEC patients. Considering the broad spectrum of MEC and the sparse research on Warthin-like MEC, further studies focus on targeted therapy to benefit patients with poor prognoses is still required.

Funding resources

This study received funding from the CAMS Innovation Fund for Medical Sciences (2019-I2M-5-038), and the Fundamental Research Funds for the Central Universities: Special Projects for Strengthening Basic Research of Peking University (BMU2019JC001).

Data availability statement

The data that support the present findings will be made available from the corresponding author upon reasonable request.

Patient consent

All pathology micrographs provided do not contain any identifying marks and are not accompanied by text that might identify the individual concerned.

CRediT authorship contribution statement

Xi Wang: Writing – review & editing, Writing – original draft, Visualization, Validation, Software, Methodology, Formal analysis, Data curation. Lingchao Liu: Visualization, Methodology. Huiying He: Writing – review & editing, Validation, Supervision, Methodology, Funding acquisition, Formal analysis, Conceptualization. Binbin Li: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Binbin Li reports financial support was provided by Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Huiying He reports financial support was provided by Peking University. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2024.e24873.

Contributor Information

Xi Wang, Email: wangxikq@stu.pku.edu.cn.

Huiying He, Email: huiyinghe@bjmu.edu.cn.

Binbin Li, Email: kqlibinbin@bjmu.edu.cn.

Appendix A. Supplementary data

The following is the Supplementary data to this article:

Multimedia component 1
mmc1.docx (31.8KB, docx)

References

  • 1.Chen M.M., Roman S.A., Sosa J.A., Judson B.L. Histologic grade as prognostic indicator for mucoepidermoid carcinoma: a population-level analysis of 2400 patients. Head Neck. 2014;36:158–163. doi: 10.1002/hed.23256. [DOI] [PubMed] [Google Scholar]
  • 2.Kalhor N., Moran C.A. Pulmonary mucoepidermoid carcinoma: diagnosis and treatment. Expet Rev. Respir. Med. 2018;12:249–255. doi: 10.1080/17476348.2018.1428563. [DOI] [PubMed] [Google Scholar]
  • 3.Granic M., Suton P., Mueller D., Cvrljevic I., Luksic I. Prognostic factors in head and neck mucoepidermoid carcinoma: experience at a single institution based on 64 consecutive patients over a 28-year period. Int. J. Oral Maxillofac. Surg. 2018;47:283–288. doi: 10.1016/j.ijom.2017.09.005. [DOI] [PubMed] [Google Scholar]
  • 4.Hay A.J., Migliacci J., Karassawa Zanoni D., McGill M., Patel S., Ganly I. Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: incidence and outcomes by site and histological type. Cancer. 2019;125:3354–3366. doi: 10.1002/cncr.32208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bundele M., Weinreb I., Xu B., Chiosea S., Faquin W., Dias-Santagata D., Leon M., Hyrcza M., Seethala R.R. Mucoacinar carcinoma: a rare variant of mucoepidermoid carcinoma. Am. J. Surg. Pathol. 2021;45:1028–1037. doi: 10.1097/PAS.0000000000001752. [DOI] [PubMed] [Google Scholar]
  • 6.Kumar R., Natarajan S., Sneha K.S., Chitra N.S., Boaz K., Manaktala N. Oncocytes in mucoepidermoid carcinoma of the palate: diagnostic challenges. Case reports in dentistry. 2017;2017:5741821–5741825. doi: 10.1155/2017/5741821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Oide T., Hiroshima K., Takahashi Y., Fugo K., Yamatoji M., Kasamatsu A., Endo-Sakamoto Y., Shiiba M., Uzawa K., Tanzawa H., et al. Mucoepidermoid carcinoma with extensive spindled morphology and melanocytic marker expression. Hum. Pathol. 2017;67:181–186. doi: 10.1016/j.humpath.2017.03.010. [DOI] [PubMed] [Google Scholar]
  • 8.Ishibashi K., Ito Y., Masaki A., Fujii K., Beppu S., Sakakibara T., Takino H., Takase H., Ijichi K., Shimozato K., et al. Warthin-like mucoepidermoid carcinoma: a combined study of fluorescence in situ hybridization and whole-slide imaging. Am. J. Surg. Pathol. 2015;39:1479–1487. doi: 10.1097/PAS.0000000000000507. [DOI] [PubMed] [Google Scholar]
  • 9.Birkeland A.C., Foltin S.K., Michmerhuizen N.L., Hoesli R.C., Rosko A.J., Byrd S., Yanik M., Nor J.E., Bradford C.R., Prince M.E., et al. Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncol. 2017;68:5–8. doi: 10.1016/j.oraloncology.2017.02.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Pérez-de-Oliveira M.E., Wagner V.P., Araújo A.L.D., Martins M.D., Santos-Silva A.R., Bingle L., Vargas P.A. Prognostic value of CRTC1-MAML2 translocation in salivary mucoepidermoid carcinoma: systematic review and meta-analysis. J. Oral Pathol. Med. 2020;49:386–394. doi: 10.1111/jop.12970. [DOI] [PubMed] [Google Scholar]
  • 11.Nordkvist A., Gustafsson H., Juberg-Ode M., Stenman G. Recurrent rearrangements of 11q14-22 in mucoepidermoid carcinoma. Cancer Genet. Cytogenet. 1994;74:77–83. doi: 10.1016/0165-4608(94)90001-9. [DOI] [PubMed] [Google Scholar]
  • 12.Tonon G., Modi S., Wu L., Kubo A., Coxon A.B., Komiya T., O'Neil K., Stover K., El-Naggar A., Griffin J.D., et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat. Genet. 2003;33:208–213. doi: 10.1038/ng1083. [DOI] [PubMed] [Google Scholar]
  • 13.Fehr A., Röser K., Heidorn K., Hallas C., Löning T., Bullerdiek J. A new type of MAML2 fusion in mucoepidermoid carcinoma. Genes Chromosomes Cancer. 2008;47:203–206. doi: 10.1002/gcc.20522. [DOI] [PubMed] [Google Scholar]
  • 14.Nakayama T., Miyabe S., Okabe M., Sakuma H., Ijichi K., Hasegawa Y., Nagatsuka H., Shimozato K., Inagaki H. Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma. Mod. Pathol. 2009;22:1575–1581. doi: 10.1038/modpathol.2009.126. [DOI] [PubMed] [Google Scholar]
  • 15.Morita M., Murase T., Okumura Y., Ueda K., Sakamoto Y., Masaki A., Kawakita D., Tada Y., Nibu K.I., Shibuya Y., et al. Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma. Histopathology. 2020;76:1013–1022. doi: 10.1111/his.14100. [DOI] [PubMed] [Google Scholar]
  • 16.Goode R.K., Auclair P.L., Ellis G.L. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 1998;82:1217–1224. doi: 10.1002/(sici)1097-0142(19980401)82:7<1217::aid-cncr2>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  • 17.Brandwein M.S., Ivanov K., Wallace D.I., Hille J.J., Wang B., Fahmy A., Bodian C., Urken M.L., Gnepp D.R., Huvos A., et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am. J. Surg. Pathol. 2001;25:835–845. doi: 10.1097/00000478-200107000-00001. [DOI] [PubMed] [Google Scholar]
  • 18.Healey W.V., Perzin K.H., Smith L. Mucoepidermoid carcinoma of salivary gland origin. Classification, clinical-pathologic correlation, and results of treatment. Cancer. 1970;26:368–388. doi: 10.1002/1097-0142(197008)26:2<368::aid-cncr2820260219>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  • 19.Katabi N., Ghossein R., Ali S., Dogan S., Klimstra D., Ganly I. Prognostic features in mucoepidermoid carcinoma of major salivary glands with emphasis on tumour histologic grading. Histopathology. 2014;65:793–804. doi: 10.1111/his.12488. [DOI] [PubMed] [Google Scholar]
  • 20.Seifert G., Bull H.G., Donath K. Histologic subclassification of the cystadenolymphoma of the parotid gland. Analysis of 275 cases. Virchows Arch. A Pathol. Anat. Histol. 1980;388:13–38. doi: 10.1007/BF00430674. [DOI] [PubMed] [Google Scholar]
  • 21.Lydiatt W.M., Patel S.G., O'Sullivan B., Brandwein M.S., Ridge J.A., Migliacci J.C., Loomis A.M., Shah J.P. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017;67:122–137. doi: 10.3322/caac.21389. [DOI] [PubMed] [Google Scholar]
  • 22.Huo Z., Wu H., Li J., Li S., Wu S., Liu Y., Luo Y., Cao J., Zeng X., Liang Z. Primary pulmonary mucoepidermoid carcinoma: histopathological and moleculargenetic studies of 26 cases. PLoS One. 2015;10 doi: 10.1371/journal.pone.0143169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Akaev I., Yeoh C.C., Brennan P.A., Rahimi S. Low grade parotid mucoepidermoid carcinoma with tumour associated lymphoid proliferation (“Warthin-like”) and CRTC1-MAML2 fusion transcript: definitive diagnosis with molecular investigation only. Oral Oncol. 2018;80:98–99. doi: 10.1016/j.oraloncology.2018.03.010. [DOI] [PubMed] [Google Scholar]
  • 24.Balasubiramaniyan V., Sultania M., Sable M., Muduly D., Kar M. Warthin-like mucoepidermoid carcinoma of the parotid gland: a diagnostic and therapeutic dilemma. Autopsy & case reports. 2019;9 doi: 10.4322/acr.2019.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bieńkowski M., Kunc M., Iliszko M., Kuźniacka A., Studniarek M., Biernat W. MAML2 rearrangement as a useful diagnostic marker discriminating between Warthin tumour and Warthin-like mucoepidermoid carcinoma. Virchows Arch. 2020;477:393–400. doi: 10.1007/s00428-020-02798-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bishop J.A., Cowan M.L., Shum C.H., Westra W.H. MAML2 rearrangements in variant forms of mucoepidermoid carcinoma: ancillary diagnostic testing for the ciliated and warthin-like variants. Am. J. Surg. Pathol. 2018;42:130–136. doi: 10.1097/PAS.0000000000000932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hang J.F., Shum C.H., Ali S.Z., Bishop J.A. Cytological features of the Warthin-like variant of salivary mucoepidermoid carcinoma. Diagn. Cytopathol. 2017;45:1132–1136. doi: 10.1002/dc.23785. [DOI] [PubMed] [Google Scholar]
  • 28.Heatley N., Harrington K.J., Thway K. Warthin tumor-like mucoepidermoid carcinoma. Int. J. Surg. Pathol. 2018;26:31–33. doi: 10.1177/1066896917724889. [DOI] [PubMed] [Google Scholar]
  • 29.Zhang D., Liao X., Tang Y., Meyer R.G., Dl V.A.N.D., Liu X., Islam M.N., Lai J. Warthin-like mucoepidermoid carcinoma of the parotid gland: unusual morphology and diagnostic pitfalls. Anticancer Res. 2019;39:3213–3217. doi: 10.21873/anticanres.13461. [DOI] [PubMed] [Google Scholar]
  • 30.Grasl S., Janik S., Faisal M., Grasl M.C., Pammer J., Weinreb I., Fischer G., Kim J., Hosni A., de Almeida J.R., et al. Influence of grading on management and outcome in mucoepidermoid carcinoma of the parotid-A multi-institutional analysis. Laryngoscope. 2022;133:124–132. doi: 10.1002/lary.30135. [DOI] [PubMed] [Google Scholar]
  • 31.Nishimura H., Kawata R., Kinoshita I., Higashino M., Terada T., Haginomori S.I., Tochizawa T. Ear Nose Throat J; 2022. (Management for Warthin Tumor of the Parotid Gland: Surgery or Observation. A 21-Year Retrospective Study of 387 Cases). 1455613221080927. [DOI] [PubMed] [Google Scholar]
  • 32.Taniuchi M., Kawata R., Terada T., Higashino M., Nishimura H., Kurisu Y., Kuwabara H., Hirose Y. Management and outcome of parotid mucoepidermoid carcinoma by histological grade: a 21-year review. Laryngoscope Investig Otolaryngol. 2022;7:766–773. doi: 10.1002/lio2.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kawata R., Kinoshita I., Omura S., Higashino M., Nishikawa S., Terada T., Haginomori S.I., Kurisu Y., Hirose Y., Tochizawa T. Risk factors of postoperative facial palsy for benign parotid tumors: outcome of 1,018 patients. Laryngoscope. 2021;131:E2857–e2864. doi: 10.1002/lary.29623. [DOI] [PubMed] [Google Scholar]
  • 34.Sučić M., Ljubić N., Perković L., Ivanović D., Pažanin L., Sučić Radovanović T., Župnić-Krmek D., Knežević F. Cytopathology and diagnostics of Warthin's tumour. Cytopathology. 2020;31:193–207. doi: 10.1111/cyt.12830. [DOI] [PubMed] [Google Scholar]
  • 35.Fehr A., Werenicz S., Trocchi P., Falk M., Friedrich R.E., Stammler A., Stang A., Oesterling F., Khil L., Stenman G., et al. Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping. Virchows Arch. 2021;479:975–985. doi: 10.1007/s00428-021-03146-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.docx (31.8KB, docx)

Data Availability Statement

The data that support the present findings will be made available from the corresponding author upon reasonable request.


Articles from Heliyon are provided here courtesy of Elsevier

RESOURCES